Dr. Sheng-Wei Pan of Taipei Veterans General Hospital, lead author of the work, emphasized that “every week of delay” matters for both patient outcomes and public health. The World Health Organization estimates that roughly one-quarter of the global population is infected with Mycobacterium tuberculosis, and 5–10% may progress to active disease. Early detection followed by antibiotic treatment can be lifesaving and can reduce onward spread.

Traditionally, TB diagnosis relies on sputum samples, which require patients to produce mucus from the lungs and airways. That approach can fail in early infection or in cases with low bacterial burden, leaving clinicians without a reliable, non-sputum alternative. A blood-based method would broaden access to testing in settings where collection and lab turnaround are limiting factors.

The study centers on a bacterial marker: 6-kDa early secreted antigenic target (ESAT-6). While ESAT-6 has been studied previously, many sensors have struggled to distinguish active pulmonary TB from latent TB infection, prior exposure without infection, TB caused by other Mycobacterium species, lung cancer, or other lung disorders. The team addressed this challenge using a biosensor designed for highly sensitive quantification of circulating ESAT-6.

Researchers measured ESAT-6 levels in blood from 217 participants with confirmed active pulmonary TB or with non-TB conditions. The control group included lung disease from non-TB Mycobacterium species, lung cancer, latent TB, exposed but uninfected individuals, and healthy participants with no known TB contact. The marker clearly separated TB from non-TB participants.

Importantly, ESAT-6 concentrations showed a stepwise pattern: lowest in uninfected contacts, intermediate in latent TB, and highest in active TB. This relationship remained robust even after accounting for variables such as age, sex, and diabetes. Because ESAT-6 originates directly from the bacteria rather than from the host immune response, the signal may better reflect disease activity.

Compared with two commonly used blood-based markers, ESAT-6 demonstrated improved discrimination among clinical TB groups. Still, the researchers note that their study design used known disease status from the outset, so prospective testing is needed to establish predictive performance over time.

While sputum cultures remain essential for confirmation and drug-resistance profiling, ESAT-6 could provide a fast, practical triage tool when sputum diagnostics are delayed or limited. The team is planning a prospective study to evaluate whether the test can guide clinical decision-making in real-world settings.

Subject of Research: Quantitative blood ESAT-6 for non-sputum identification of pulmonary tuberculosis
Article Title: Quantitative assessment of circulating blood ESAT-6 for non-sputum identification of pulmonary tuberculosis (Abstract A-097)
News Publication Date: July 28, 2026
Web References: https://posters.myadlm.org/adlm/2026/adlm-2026/4215994/sheng-wei.pan.quantitative.assessment.of.circulating.blood.esat-6.for.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dtuberculosis
References: World Health Organization estimates cited in the article; ADLM 2026 presentation details provided in the source text
Image Credits: Not provided

Keywords: tuberculosis, ESAT-6, biosensor, blood test, pulmonary TB, non-sputum diagnosis, diagnostic accuracy, latent TB, infection exposure

Tuberculosis, caused by Mycobacterium tuberculosis, is notoriously difficult to detect in its early stages due to its often asymptomatic or nonspecific clinical presentation. Traditionally, diagnosis hinges on microbiological assays or the presence of overt clinical symptoms. However, this groundbreaking research shifts the spotlight towards radiological imaging, specifically chest X-rays, as an invaluable tool for predicting disease trajectory well before clinical manifestations become apparent.

The team, led by Zhu et al., systematically analyzed chest radiographs from a vast cohort of individuals at risk of tuberculosis infection. By meticulously correlating radiographic abnormalities with longitudinal health outcomes, the study demonstrated that an abnormal chest X-ray greatly increases the likelihood of progression to active TB within a defined period. This finding underscores the crucial prognostic value of radiographic screening, especially in high-burden settings.

Sophisticated image analysis techniques played a pivotal role in this research. Utilizing advanced computational methods and machine learning algorithms, the scientists were able to discern subtle radiological patterns that might elude even experienced radiologists. These patterns, often localized and non-specific, were nevertheless predictive markers of pathology, indicating latent or incipient infection stages.

This research fills a critical gap in the continuum of tuberculosis diagnosis. While sputum tests and microbiological cultures remain the gold standard for active disease confirmation, they offer limited utility in predicting future disease onset in asymptomatic individuals. The incorporation of chest X-ray abnormalities as prognostic indicators bridges this gap, providing a proactive lens through which clinicians can identify and monitor high-risk patients more effectively.

Another noteworthy aspect of the study lies in its epidemiological breadth. By encompassing diverse populations with varying TB exposure risks, the researchers ensured that their findings are robust and generalizable. This broad approach enables the adaptation of their screening protocols across different healthcare infrastructures, potentially revolutionizing how TB surveillance is conducted globally.

Moreover, the research outlines important clinical implications for TB control programs. Early identification of individuals with abnormal chest X-rays enables targeted preventive therapy, reducing the reservoir of latent infection and curtailing transmission chains. This strategic shift from reactive to proactive care could significantly impact disease incidence, particularly in regions with limited access to comprehensive diagnostic resources.

From a technical perspective, the study rigorously evaluated interobserver variability in chest X-ray interpretation, establishing that even minor abnormalities carry prognostic significance. The authors advocate for enhanced radiological training and standardized reporting protocols to maximize the clinical utility of radiographic data. This calls for integration of emerging technologies like artificial intelligence to augment human expertise in diagnostic accuracy.

The findings also bear relevance for public health policymakers, emphasizing resource allocation towards improving radiological infrastructure and training. Given the cost-effectiveness of chest X-rays relative to molecular tests, scaling up radiographic screening can be a feasible and impactful strategy in lower-resource settings, enabling earlier interventions and better outcomes.

The potential for leveraging this radiological prognostic marker extends beyond TB. The methodological framework developed by Zhu et al. could be adapted to other infectious or chronic lung diseases where early subtle imaging changes presage clinical deterioration, marking a new era in personalized radiology-driven healthcare.

Academic and clinical communities have lauded this research for its innovation and translational potential. The study’s robust statistical analyses and longitudinal design lend credibility and rigor, making it a seminal work that will likely influence future TB diagnosis guidelines and spark further research into radiology-based predictive diagnostics.

In summary, this study redefines the utility of chest X-rays from a mere diagnostic tool to a prognostic instrument with considerable predictive accuracy for tuberculosis development. By identifying abnormal radiological signals early, clinicians can implement timely interventions, ultimately reducing disease burden and transmission worldwide.

As tuberculosis continues to pose a formidable public health threat, particularly in under-resourced environments, innovations like those presented in this research provide hope for more effective management strategies. The integration of chest X-ray abnormalities into TB screening protocols could transform clinical practice and substantially accelerate global efforts to curb this devastating disease.

Future research stemming from this study could delve deeper into the mechanistic underpinnings of these radiological anomalies, potentially correlating imaging findings with immunological and microbiological markers to refine risk stratification further. Such multidimensional approaches promise to deepen understanding and heighten predictive capabilities for tuberculosis and beyond.

This work, therefore, represents a landmark advance, kindling new possibilities in the fight against tuberculosis and underscoring the enduring value of radiological imaging in infectious disease management. The adoption of these insights by healthcare systems worldwide could herald a new chapter in global health security.

Subject of Research: Prognostic value of abnormal chest X-rays in predicting tuberculosis development

Article Title: Prognostic value of an abnormal chest X-ray result in predicting the development of tuberculosis

Article References:
Zhu, P., Chen, X., Pan, J. et al. Prognostic value of an abnormal chest X-ray result in predicting the development of tuberculosis. Nat Commun 16, 9866 (2025). https://doi.org/10.1038/s41467-025-64834-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-64834-9

Historically, tuberculosis (TB) diagnosis has depended on sputum specimens, a viscous mucus originating from the lungs and lower respiratory tract. While sputum samples are ideal because they harbor ample quantities of TB bacteria necessary for assay sensitivity, their collection is cumbersome, often requiring trained personnel and patient cooperation. Such collection challenges lead to inefficiencies in large-scale screening programs. More critically, sputum testing is not feasible in approximately 25% of symptomatic patients and nearly 90% of those without symptoms, creating a diagnostic void that contributes to an estimated four million undiagnosed TB cases annually on a global scale.

Addressing these critical gaps, the Tulane research team leveraged prior CRISPR diagnostic platforms and refined them to amplify detection sensitivity in samples with low bacterial loads—specimens traditionally considered unsuitable for reliable TB detection, such as stool, cerebrospinal fluid, and notably, tongue swabs. These biologically diverse matrices pose significant sensitivity challenges due to dilute bacterial DNA concentrations and the presence of PCR inhibitors, necessitating a more robust molecular detection approach.

Published in the prestigious journal Nature Communications, the study showcases the tailored CRISPR assay’s performance across several clinical sample types. Most notably, tongue swabs—non-invasive, painless, and easily collectible specimens—yielded a TB detection sensitivity of 74%, markedly surpassing traditional methods which hovered around 56%. This enhancement represents a paradigm shift, pointing toward a feasible, scalable, and patient-friendly approach to TB screening that can function outside conventional healthcare facilities.

Furthermore, the assay demonstrated exceptional sensitivity when applied to other challenging sample types. Respiratory samples exhibited a detection sensitivity of 93%, pediatric stool samples showed 83%, and adult cerebrospinal fluid samples also achieved 93% sensitivity. These figures underscore the assay’s versatility across a spectrum of patient groups, including children, individuals living with HIV, and patients with extrapulmonary TB—all populations that commonly face sputum collection difficulties.

At the core of this breakthrough is a CRISPR diagnostic platform termed ActCRISPR-TB, designed to enhance the amplification and detection of pathogen-associated DNA via a multi-guide RNA Cas12a system. This system exploits the unique trans-cleavage activity of Cas12a endonuclease, which, upon activation by target DNA binding via multiple guide RNAs, indiscriminately cleaves single-stranded DNA reporters, generating a measurable signal. By preferentially favoring trans-cleavage over cis-cleavage activity, the assay attains heightened sensitivity, effectively detecting even trace amounts of TB bacterial DNA.

To facilitate decentralized testing, the researchers innovated a streamlined “one-pot” diagnostic procedure. This entails combining the patient-collected tongue swab directly with a preloaded reaction tube containing freeze-dried reagents and a lateral flow test strip. The tube is then incubated under controlled conditions for roughly 45 minutes, after which the test strip visually indicates TB presence via colorimetric bands. Notably, this workflow emulates the user-friendliness of rapid COVID-19 antigen tests, eliminating the necessity for elaborate laboratory infrastructure or highly trained personnel.

The advantages of a non-sputum, point-of-care test extend beyond accessibility. Conventional nucleic acid amplification tests for TB sputum samples often require lengthy processing times and specialized equipment that challenge widespread deployment. Conversely, the ActCRISPR-TB assay drastically reduces turnaround time, delivering definitive results in under an hour. This rapidity is poised to accelerate clinical decision-making, enabling prompt initiation of treatment regimens and curbing transmission within communities.

Tulane’s research represents an integral component of a broader vision led by Dr. Tony Hu, whose laboratory is pioneering portable TB diagnostics that integrate advanced molecular biology techniques with user-centric design. Beyond sample versatility and assay sensitivity, Hu’s team has developed handheld devices, comparable in size to smartphones, and even electricity-free units, tailored for environments lacking reliable power sources. Additionally, their integration of artificial intelligence algorithms to assess drug resistance profiles from genetic data ensures patients receive customized therapies swiftly, a critical step in combating multidrug-resistant tuberculosis strains.

The persistent global burden of tuberculosis—still one of the world’s deadliest infectious diseases—necessitates innovative diagnostic tools that transcend traditional clinical settings. As Dr. Hu emphasized, over 10 million individuals develop active TB annually, yet a staggering 40% remain undiagnosed due to the inadequacies of current detection paradigms. Non-invasive, efficient, and accessible tests such as ActCRISPR-TB hold promise to bridge this gap by enabling large-scale community screenings that identify hidden reservoirs of infection.

Equally promising is the potential impact on vulnerable populations who traditionally face diagnostic neglect. Children, people with HIV, and those with extrapulmonary TB often cannot produce sputum, rendering existing diagnostic options ineffective or inaccessible. The validated performance of the new CRISPR assay in pediatric stool and spinal fluid samples reflects a critical advance toward inclusive testing strategies that do not discriminate based on patient-specific sample availability constraints.

From a molecular standpoint, the strategic use of multiple guide RNAs in the Cas12a system enhances target recognition fidelity and signal amplification, mitigating false negatives commonly associated with low-copy-number pathogens. This technical refinement elevates confidence in test results and aligns with stringent clinical standards. Moreover, the entire assay’s simplification into a single-tube format not only conserves reagents and reduces contamination risks but also minimizes procedural errors, a frequent hindrance in decentralized testing environments.

While additional validation and regulatory approvals lie ahead, the revolutionary prospects introduced by this research signal a new chapter in tuberculosis control. By democratizing TB diagnostics through technology that fits into the palm of a hand and can be deployed in the most remote settings, the pathway to ending TB becomes clearer and more attainable.

As the study’s lead author, Dr. Zhen Huang, aptly noted, the painless and straightforward nature of tongue swabs effectively removes traditional barriers to sample collection. This innovation opens the gateway for widescale testing campaigns that were previously unimaginable in under-resourced regions. Combined with rapid turnaround times and high diagnostic accuracy, such advances could dramatically reshape public health responses to tuberculosis worldwide.

Ultimately, the Tulane team’s dual focus on molecular innovation and pragmatic deployment tools epitomizes the future of infectious disease diagnostics. By focusing on community-reaching formats rather than centralized labs, they offer a tangible solution to one of the most stubborn public health challenges of our time. With continued development, the ActCRISPR-TB assay and accompanying technologies could establish a new global standard for TB detection, cost-effectiveness, and accessibility, bringing us markedly closer to a world free of tuberculosis.

Subject of Research: Tuberculosis diagnostics, CRISPR-based pathogen detection

Article Title: Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans- versus cis-cleavage

News Publication Date: 17-Sep-2025

Web References: 10.1038/s41467-025-63094-x

Keywords: Tuberculosis, Respiratory disorders, Infectious diseases, Medical diagnosis, Biotechnology, Clinical medicine, Respiratory system, Epidemiology

Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, affects millions worldwide with 10.8 million new cases and approximately 1.25 million deaths recorded in 2023 alone. The disease’s complexity lies partly in its ability to remain latent within an individual for years without symptoms before potentially activating and causing severe illness. Detecting the dormant form of TB infection—often called latent TB infection (LTBI)—is vital for controlling the spread of the disease, particularly in high-risk populations such as migrants from endemic areas. However, existing diagnostic algorithms typically separate tests for latent and active TB, overlooking the interplay between the two stages and reducing overall diagnostic efficacy.

The Queen Mary-led study, recently published in the European Respiratory Journal, represents the first comprehensive analysis combining 13 different TB tests described across 437 original research articles and systematic reviews. The researchers employed advanced decision tree analytical modeling techniques to assess not only the sensitivity and specificity of individual tests but also the synergistic effects of combining them. Their rigorous meta-analysis revealed that integrating immunological assays for latent infection—specifically interferon gamma release assays (IGRAs)—with classical screening tools like chest X-rays and sputum cultures markedly improves the accuracy of detecting active TB cases, including difficult-to-diagnose extrapulmonary and pediatric TB.

Traditionally, TB diagnostics have bifurcated into methods targeting active disease, such as radiological imaging and microbiological culture, and those aimed at identifying latent infection, including the tuberculin skin test (TST) and IGRAs. While these tests were developed for distinct clinical purposes, this research challenges their isolated use. It demonstrates that TBI (tuberculosis infection) tests, when performed concurrently with active TB diagnostics, provide additive value by revealing immunological signatures indicating both ongoing infection and latent reservoirs. This dual detection not only enhances early identification but also reduces false-positive rates, minimizing unnecessary treatments that carry their own risks.

One of the pivotal findings of the study is the potential of IGRAs—a blood test measuring immune response to TB antigens—to elevate screening performance in migrant populations from high TB burden countries. Migrants often represent a substantial fraction of active TB cases in many low-incidence countries, yet current screening regimens may inadequately capture infection nuances within this group. Dr. Dominik Zenner, the study’s lead author and Clinical Reader in Infectious Disease Epidemiology, emphasizes that applying combined screening methodologies has “high accuracy for migrants” and can dramatically improve both individualized patient care and overarching public health benefits by curbing transmission chains.

The significance of this research extends beyond theoretical modeling to direct clinical and policy implications. Previous TB control strategies endorsed by the World Health Organization (WHO) and other global health bodies have not fully incorporated immunological tests for latent infection into standard active TB screening algorithms. By advocating for an inclusive approach that integrates IGRAs with conventional diagnostics, this study provides robust evidence supporting guideline revisions worldwide. Mario Raviglione, former Director of the WHO Global Tuberculosis Programme, lauds the study as “a sophisticated and well-thought investigation” with “major implications for clinical and public health practice,” underscoring the potential for widespread policy transformation.

Additionally, the study sheds light on the diagnostic challenges posed by extrapulmonary TB—cases where the infection manifests outside the lungs—and pediatric TB, both of which have historically evaded reliable detection. The enhanced sensitivity offered by combining immunological tests with standard diagnostics can facilitate earlier detection of these often overlooked forms of the disease, allowing for timely treatment interventions that prevent morbidity and mortality.

The public health importance of accurate and early TB diagnosis is underscored by epidemiological data from East London, which currently records the highest rates of newly diagnosed TB cases in Western Europe. TB disproportionately impacts deprived communities in this region, highlighting a critical need for improved screening practices tailored to vulnerable populations. Researchers at Queen Mary University have actively collaborated with Barts Health NHS Trust to establish a new centre of excellence for TB research and treatment, aiming to translate these scientific advances into effective clinical and community strategies.

By simultaneously detecting active and latent TB infection through optimized test combinations, the novel screening algorithm challenges long-standing diagnostic paradigms. It moves the field towards a more holistic, immunologically informed approach that acknowledges the continuum of Mycobacterium tuberculosis infection states. This reconceptualization not only has the potential to save countless lives through earlier treatment but also addresses key epidemiological drivers by intercepting latent cases before disease activation and transmission occur.

From a methodological perspective, the study’s reliance on systematic review and meta-analytic techniques confers exceptional rigor, as it synthesizes a vast body of evidence while applying sophisticated statistical modeling. Decision tree analyses allowed the team to simulate and compare multiple screening algorithm permutations, accurately projecting both their diagnostic yield and implications for false positive rates. This methodology exemplifies the power of integrating epidemiological data with cutting-edge analytical frameworks to resolve complex clinical challenges.

In conclusion, the breakthrough findings by the Queen Mary University of London team pave the way for a new era in TB diagnosis—one that unites immunological and traditional diagnostics to deliver a comprehensive and accurate detection strategy. Their research not only promises to revolutionize clinical pathways for migrants and other high-risk groups but also signals a critical step forward in global TB eradication efforts. Implementation of these algorithms could reduce TB incidence worldwide, saving lives and alleviating the burden on healthcare systems.

Subject of Research: People

Article Title: How to diagnose TB in migrants? A systematic review of reviews and decision tree analytical modelling exercise to evaluate properties for single and combined TB screening tests

News Publication Date: 24-Apr-2025

Web References: https://doi.org/10.1183/13993003.02000-2024

References: Zenner, D. et al. “How to diagnose TB in migrants? A systematic review of reviews and decision tree analytical modelling exercise to evaluate properties for single and combined TB screening tests.” European Respiratory Journal. DOI: 10.1183/13993003.02000-2024

Keywords: Tuberculosis, Public health, Disease control, Diagnostic accuracy

In a groundbreaking development, researchers at Tulane University have made substantial strides toward addressing this global health crisis through artificial intelligence. They have introduced a novel diagnostic methodology that significantly enhances the detection of genetic markers associated with antibiotic resistance in both Mycobacterium tuberculosis and Staphylococcus aureus. This innovative technique, which harnesses the power of machine learning, has the potential to revolutionize treatment strategies and improve patient outcomes by facilitating faster, more accurate diagnoses of resistant strains.

The research team’s findings are detailed in a study published in Nature Communications, where they unveil a new analytical approach known as the Group Association Model (GAM). Unlike conventional methods that rely heavily on prior knowledge of resistance mechanisms, GAM utilizes machine learning to identify genetic mutations that are empirically linked to drug resistance. This flexibility allows the model to uncover previously unidentified genetic alterations, paving the way for more comprehensive assessments of antibiotic susceptibility.

Traditional resistance detection methods, widely employed by health organizations like the WHO, often suffer from significant drawbacks. For instance, culture-based tests can be time-consuming, delaying the initiation of appropriate treatment in critically ill patients. Moreover, the limitations of some DNA-based tests result in the oversight of rare mutations that may play a crucial role in dictating antibiotic efficacy. The Tulane team’s GAM effectively addresses these issues by analyzing whole-genome sequences and dissecting variations among bacterial strains harboring different resistance patterns. This comparative analysis enables the identification of specific genetic changes that consistently indicate resistance to particular antibiotics.

Senior author Tony Hu, who serves as the Weatherhead Presidential Chair in Biotechnology Innovation and leads the Tulane Center for Cellular & Molecular Diagnostics, explains the innovative nature of this research. He elucidates this as leveraging the entire genetic fingerprint of the bacteria to discern the mechanisms conferring immunity against certain antibiotics. The brilliance of GAM lies in its ability to autonomously recognize resistance patterns without manual input, marking a significant technological advancement in the diagnostic landscape.

In the pivotal phase of their study, the researchers applied GAM to a vast dataset, encompassing over 7,000 strains of Mycobacterium tuberculosis alongside nearly 4,000 strains of Staphylococcus aureus. The results were illuminating: GAM not only matched but in many instances surpassed the accuracy of the WHO’s resistance database. Furthermore, it exhibited a remarkable reduction in false positives—erroneous lab findings that can lead to misdiagnoses and inappropriate treatments.

Lead author Julian Saliba, a graduate student at the Tulane Center for Cellular and Molecular Diagnostics, highlights the critical implications of their findings. Current genetic testing methodologies can mistakenly classify certain bacteria as resistant, inadvertently jeopardizing patient care. The introduction of GAM, with its refined accuracy, lessens the likelihood of misdiagnoses, ultimately resulting in more appropriate and effective treatment adjustments.

The significance of these advancements extends beyond mere diagnostics. Combining GAM with machine learning enhances the predictive capabilities regarding drug resistance, even when data may be incomplete or limited. Validation studies conducted using clinical samples from China yielded promising results, with the GAM-enhanced model demonstrating superior predictive power for resistance to essential front-line antibiotics compared to existing WHO-based methods. This could prove vital in clinical scenarios where timely intervention is crucial, particularly as antibiotic-resistant infections gain ground.

The ability of GAM to detect resistance patterns independent of expert-defined guidelines opens a wide array of possibilities. With its adaptability, the model could potentially be scaled and applied to other bacterial species that pose rising threats, such as those related to agriculture. As antibiotic resistance remains a persistent issue affecting both human health and food security, solutions that extend to crops are critically needed.

The researchers emphasize the importance of remaining proactive in the ongoing battle against evolving drug-resistant infections. As Saliba aptly puts it, the development of this novel diagnostic tool is crucial; it represents an essential step in the fight to stay one step ahead of the rapidly changing landscape of antibiotic resistance. The introduction of GAM signifies a paradigm shift in our approach to tackling bacterial infections, offering hope for improved outcomes for patients grappling with these pernicious pathogens.

Integrating artificial intelligence with genetic analysis may usher in a new age of precision medicine, equipping healthcare providers with the tools necessary to effectively combat drug-resistant infections. Such innovations underscore the critical role of research and innovation in addressing global health challenges—providing tangible solutions to problems that threaten to complicate healthcare delivery and exacerbate public health crises. Through resilience and continued exploration of these scientific frontiers, there lies a promising horizon in the prevention and treatment of antibiotic-resistant infections.

With the refinement of GAM and its potential implications stretching beyond tuberculosis and staph infections, the Tulane University team represents a beacon of hope in overcoming one of the most pressing health challenges of our time. As the burden of antibiotic resistance grows heavier, the development of rapid, reliable diagnostic solutions is imperative for safeguarding public health and ensuring better patient care. The work undertaken by these researchers reflects the fusion of technology and biology, paving the way for future innovations that could fundamentally alter the landscape of infectious disease treatment.

Subject of Research: Enhanced diagnosis of multi-drug-resistant bacteria using machine learning
Article Title: Enhanced diagnosis of multi-drug-resistant microbes using group association modeling and machine learning
News Publication Date: 25-Feb-2025
Web References: 10.1038/s41467-025-58214-6
References: N/A
Image Credits: N/A
Keywords: Drug resistance, Antibiotic resistance, Machine learning, Genetic methods, Bacterial infections, Precision medicine, Tuberculosis, Public health, Diagnostic tools, Infectious diseases.